Trial Profile
A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs I-131-Apamistamab (Primary) ; Asparaginase; Azacitidine; Carboplatin; Cladribine; Clofarabine; Cyclophosphamide; Cytarabine; Daunorubicin; Decitabine; Doxorubicin; Enasidenib; Etoposide; Fludarabine; Gemtuzumab ozogamicin; Gilteritinib; Idarubicin; Ivosidenib; Midostaurin; Mitoxantrone; Sorafenib; Tioguanine; Topotecan; Venetoclax
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms Iomab-B SIERRA; SIERRA; SIERRA in AML
- Sponsors Actinium Pharmaceuticals
- 01 Apr 2024 According to Actinium Pharmaceuticals media release, Results from this study have been accepted for oral presentation at the 50th Annual meeting of the European Bone Marrow Transplant Society (EBMT) being held April 14 to 17, 2024, in Glasgow, Scotland.
- 01 Apr 2024 Results resented in Actinium Pharmaceuticals media release,
- 26 Feb 2024 According to Actinium Pharmaceuticals media release, new analysis from this trial were presented at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT (American Society for Transplantation and Cellular Therapy and CIBMTR (Center for International Blood and Marrow Transplant Research).